Predictive Oncology to Launch AI-Driven ChemoFx® Assay in Europe, Expanding Personalized Cancer Treatment

Predictive Oncology Expands to Europe with AI-Driven Cancer Treatment Tool

Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, has announced plans to launch its ChemoFx® drug response assay in Europe while expanding its availability in the United States 1

1

. This move marks a significant step in the company's mission to revolutionize personalized cancer treatment and streamline drug discovery processes.

The ChemoFx® Assay: A Breakthrough in Personalized Medicine

The ChemoFx® assay is a treatment selection marker that quantifies an individual cancer patient's in vitro tumor response to various chemotherapeutic agents 1

1

. By testing multiple chemotherapies on a patient's cancer cells before treatment selection, the assay helps determine which therapies are more likely to be effective, potentially improving patient outcomes.

Dr. Arlette Uihlein, Senior Vice President of Translational Medicine and Medical Director at Predictive Oncology, emphasized the critical role of drug response results in the company's live tumor cell platform 1

1

. This platform utilizes AI to create predictive models of drug response, aiming to streamline and de-risk the drug discovery process.

Targeting a Significant Market

The launch in Europe targets a substantial market, with an estimated 250,000 gynecologic cancer cases diagnosed annually across the continent 1

1

. In the United States, nearly 115,000 new gynecological cancer cases are diagnosed each year 2

2

. Predictive Oncology's biobank, containing approximately 150,000 live cell tumor samples, positions the company uniquely to address this market 2

2

.

AI and Machine Learning: The Core of Predictive Oncology's Approach

Predictive Oncology's AI and machine learning platform has been validated against 175 FDA-approved drugs and 130 primary samples from ovarian tumors 1

1

. This validation underscores the potential of the company's technology in predicting drug responses and patient outcomes.

Financial Implications and Market Position

While Predictive Oncology faces current profitability challenges, the company's stock has shown strong momentum with a 45% gain year-to-date 2

2

. The ChemoFx® assay has previously generated over $25 million annually in gross revenues, indicating significant potential for future earnings 1

1

.

Expanding Applications and Future Prospects

Beyond its immediate application in treatment selection, the ChemoFx® assay and associated data sets have potential applications in clinical trial design, biomarker discovery, and companion diagnostic development 1

1

. This versatility positions Predictive Oncology at the forefront of AI-driven oncology solutions.

As Predictive Oncology expands its presence in Europe and enhances its offerings in the United States, the company continues to demonstrate its commitment to integrating AI into personalized medicine. This expansion represents a significant step forward in the ongoing effort to improve cancer treatment options and outcomes for patients worldwide.